A Phase II Study of Sapanisertib in People with Squamous Non-Small Cell Lung Cancer


Full Title

A Randomized, Open-Label Phase 2 Study of the TORC 1/2 Inhibitor Sapanisertib in Relapsed/Refractory NFE2L2 (NRF2)-Mutated and Wild-Type (WT) Squamous Non-Small Cell Lung Cancer (sqNSCLC)


The purpose of this study is to assess the safety and effectiveness of the drug sapanisertib in people with advanced squamous non-small cell lung cancer that has come back or continued to grow despite treatment. Sapanisertib blocks a protein called mTOR. When this protein is blocked, the genes that cause cancer cells to grow and divide are not able to function, which may make cancer cells stop growing or die. Sapanisertib is taken orally (by mouth).


To be eligible for this study, patients must meet several requirements, including:

  • Participants must have recurrent or persistent metastatic squamous cell lung cancer and must have previously received chemotherapy and immunotherapy.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for people age 18 and older.


For more information about this study and to ask about eligibility, please contact the office of Dr. Paul Paik at 646-608-3759.





Disease Status

Relapsed or Refractory